Recent research on NF1-deficient MPNST indicated that this subtype develops resistance to MEK inhibitor treatment partly by increasing PDGFRβ transcription and RAF dimer formation. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.